JBIO Fees and Costs — Defiance Nasdaq Junior Biotechnology ETF

Data updated: 2021-11-29

The net expense ratio is 0.45%. There are no sales loads or redemption fees. In fiscal 2020 the fund paid $3K in broker commissions, 0.0702% of average net assets, and portfolio turnover was 66%.

JBIO Fees and Expenses

Annual operating expenses and sales charges of JBIO. Prospectus, as of April 30, 2021.

Annual operating expenses
Management fee0.45%
12b-1 fee0.00%
Other expenses0.00%
Gross expense ratio0.45%
Fee waiver—
Net expense ratio0.45%
Sales charges
Max front load—
Max deferred load—
Redemption fee—
Expense limitation in place (N-CEN)No
Fees waived or reduced during the yearNo
Waived fees subject to recoupmentNo

JBIO Costs Over Time

On $10,000 invested in JBIO, assuming 5% a year before costs, total costs come to $329 over 5 years, cutting the return by 0.55% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Fund expenses (net expense ratio 0.45%)$47$148$258
Trading costs (broker commissions)$7$23$40
Lost growth on money paid in costs$0$8$30
Total costs$55$180$329
Value after costs$10,445$11,397$12,434
Impact on return, per year0.55%0.55%0.55%

JBIO Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2020.

  • Explicit cost rate (commissions ÷ average net assets): 0.0702%
  • Total broker commissions: $3K
  • Bought from dealers (principal trades, not a cost): —
  • Portfolio turnover (prospectus): 66%
  • Securities lending: none during the year

JBIO Agency Brokers

Commissions paid.

BrokerAmountShare
JANE STREET EXECUTION SERVICES, LLC$3K99.18%
MERRILL LYNCH PROFESSIONAL CLEARING CORP.$260.82%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.